Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rapid quantification of quinine and its major metabolite (3S)-3-hydroxyquinine in diluted urine by UPLC-MS/MS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Characterization of a liposome-based formulation of oxaliplatin using capillary electrophoresis: encapsulation and leakage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Challenges in conducting paediatric trials with off-patent drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. A Tablet App Supporting Self-Management for People With Dementia: Explorative Study of Adoption and Use Patterns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

To attain effective and safe pharmacotherapy, formulations in (pre)term neonates should enable extensive dose flexibility. During product development and subsequent authorization and clinical use of such formulations, there is also a need for informed decisions on excipient exposure: in addition to the need to improve the knowledge on active compounds, there is a similar need to improve the knowledge on excipients in neonates. Excipients are added to formulations as co-solvent, surfactant, preservative, colorant and/or sweetener as vehicle(s) to result in a suitable (e.g. taste, shelf life, stability) product. Progress has been made in the awareness, knowledge and access to this knowledge on the clinical pharmacology of excipients in neonates. This is thanks to different initiatives focussing on epidemiological data, excipient pharmacokinetics, or building datasets to create this knowledge. We highlight the Safe Excipient Exposure in Neonates and Small Children (SEEN) and propylene glycol project to illustrate the feasibility to build knowledge, and discuss the methods applied and problems observed during these studies. The information generated in these and other studies (European Study on Neonatal Exposure to Excipients, ESNEE) should be integrated in repositories like the Safety and Toxicity of Excipients for Paediatrics (STEP) to facilitate access to all stakeholders. This merged knowledge should have impact and assist in improving the quality of risk assessment and decision making during drug development, applying a risk-benefit framework (explicit justification of excipients, plan product development early and engage all stakeholders, data sharing and modeling, challenges related to new excipients, context sensitive risk-benefit analysis).

OriginalsprogEngelsk
TidsskriftJournal of Pharmaceutical and Biomedical Analysis
Vol/bind32
Udgave nummer4
Sider (fra-til)251-258
Antal sider8
ISSN1178-2595
DOI
StatusUdgivet - 2018

ID: 55742747